The company experienced sharply higher costs during this period, prompting a revision of its full-year cost guidance ... for the stock and a subsequent re-rating. Gain an edge in your investment ...

Cidara Therapeutics' CD388 is aimed at providing universal protection with a single yearly dose for each flu season. See why ...

To continue offering equitable and reliable access to family planning, this level of investment must be sustained,” Dr. Oluga ...

Mueller Water Products shows strong growth driven by demand & efficiency. The current valuation suggests a 'hold' rating for ...

CVS is trading at a trailing 12-month price-to-earnings, a commonly used multiple for valuing healthcare stocks, of 9.65X, ...

Eleven-year follow-up data continue to show the invasive disease-free survival benefit for node-positive patients seen in previous analyses.

Lam Research CorporationLRCX has seen its share price soar 18.4% over the past month. This surge has significantly ...

Nvidia's earnings beat sent the stock up nearly 5% after-hours, and news that a US court has moved to block reciprocal ...

Azul S.A. (AZUL) reported lower-than-expected first-quarter 2025 results, wherein the company’s bottom line and top line ...

The average monthly check for retired workers is on track to cross a psychologically important level that's not been ...

Daniel Avigad, manager of the TM Lansdowne European Special Situations Fund, discusses Europe's investment potential with ...

We are all in the blast radius of Trump’s tax-cut bill, which Catherine Rampell calls ‘transfer of wealth from the poor to ...